Tag: PURE EP

BioSig Achieves First Commercial Sale of Three PURE EP Systems

Sale Marks Milestone for Company’s Commercial expansion at leading Center of Excellence Westport, CT, Dec. 11, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of […]

BioSig Releases PURE EP Study Abstract with Data Presented at European Society of Cardiology’s ‘ESC Congress 2020’

Positive responses confirm that the PURE EP signals are preferred to conventional sources of intracardiac signals in a blinded, independent analysis. Abstract concludes PURE EP™ System is able to produce reliable and high-quality signals when compared to the available standard of care systems. Westport, CT, Sept. 15, 2020 (GLOBE NEWSWIRE) […]

BioSig Completes 100th Patient Case with PURE EP(TM) System

WESTPORT, Feb. 19, 2020 (GLOBE NEWSWIRE) — Commercialization and install plan ahead of schedule Installations at new centers are driving patient enrollments and clinical data collection BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal […]

BioSig Awarded Additional US Patent Claims for its PURE EP(TM) System

Westport, CT, Jan. 14, 2020 (GLOBE NEWSWIRE) — Company allowed a fifth utility patent Claims address methods for removing voltage offset from biomedical signals Eleven additional patent applications covering PURE EPTM System are currently pending BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary […]

BioSig Technologies Signs Three New Licensing Agreements with Mayo Clinic

Westport, CT, Nov. 26, 2019 (GLOBE NEWSWIRE) — ·New areas of collaboration identified between Mayo Clinic and BioSig ·Focus on previously untapped arrhythmia treatments ·Additional development areas covering novel therapies for autonomic nervous system disease BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a […]

BioSig Commences Clinical Trial Enrollment for PURE EP System

Westport, CT, Nov. 21, 2019 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company commenced its […]

BioSig Allowed Additional Foundational US Patent for its PURE EP(tm) System

Westport, CT, Aug. 01, 2019 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the US Patent Office has allowed another foundational patent including additional 29 patent claims […]

BioSig Technologies, Inc. to Receive 15 Units of PURE EP™ System from Manufacturer for Commercial Installation – Corrected Version

Westport, CT, July 15, 2019 (GLOBE NEWSWIRE) — 1) New units to be prepped for next phase of targeted commercial launch strategy 2) Company includes 3 additional hospitals to its list of medical institutions for delivery in 2019 to demonstrate the technology 3) Proprietary device is designed to record and display […]

BioSig Allowed a U.S. Patent for PURE EP™ Simulator

Santa Monica, CA, June 06, 2019 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the U.S. Patent & Trademark Office allowed a U.S. patent application covering its […]